{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=23",
    "query": {
      "condition": "Phase I",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 18748,
    "total_pages": 1875,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-10T15:19:02.329Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04152473",
      "title": "Safety and Tolerability of Oral Proglumide for NASH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Proglumide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 18,
      "start_date": "2019-12-13",
      "completion_date": "2022-09-09",
      "has_results": false,
      "last_update_posted_date": "2022-10-13",
      "last_synced_at": "2026-11-10T15:19:02.329Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04152473"
    },
    {
      "nct_id": "NCT01110083",
      "title": "First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "EMD 1204831",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2010-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-10-22",
      "last_synced_at": "2026-11-10T15:19:02.329Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01110083"
    },
    {
      "nct_id": "NCT05088356",
      "title": "Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Cell Transplantation (HCT)",
        "Advanced Hematologic Malignancies",
        "Acute Leukemia",
        "Chronic Myelogenous Leukemia",
        "Myelodysplastic Syndromes",
        "Myeloproliferative Disorders"
      ],
      "interventions": [
        {
          "name": "Purified regulatory T-cells (Treg) plus CD34+ HSPC",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "CliniMACS CD34 Reagent System",
          "type": "DEVICE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Plerixafor",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 66,
      "start_date": "2021-09-07",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-11-10T15:19:02.329Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05088356"
    },
    {
      "nct_id": "NCT05288556",
      "title": "Safety and Efficacy of Enteral Feeding Tube Stoma Site Accessory",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Feeding Tube Complication"
      ],
      "interventions": [
        {
          "name": "Placement of stoma site enteral feeding tube accessory",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Eric Yudelevich",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "22 Years to 85 Years"
      },
      "enrollment_count": 5,
      "start_date": "2022-04-22",
      "completion_date": "2023-09-11",
      "has_results": true,
      "last_update_posted_date": "2025-07-25",
      "last_synced_at": "2026-11-10T15:19:02.329Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05288556"
    },
    {
      "nct_id": "NCT05242822",
      "title": "A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Intrahepatic Cholangiocarcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "KIN-3248",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kinnate Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2022-03-29",
      "completion_date": "2024-10-03",
      "has_results": false,
      "last_update_posted_date": "2025-05-07",
      "last_synced_at": "2026-11-10T15:19:02.329Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Jacksonville, Florida + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05242822"
    },
    {
      "nct_id": "NCT06555822",
      "title": "A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "AZD5004",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 31,
      "start_date": "2024-08-15",
      "completion_date": "2025-03-06",
      "has_results": false,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-11-10T15:19:02.329Z",
      "location_count": 1,
      "location_summary": "Brooklyn, Maryland",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06555822"
    },
    {
      "nct_id": "NCT01323751",
      "title": "Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "ACY-1215",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2011-07",
      "completion_date": "2016-12-03",
      "has_results": false,
      "last_update_posted_date": "2017-04-06",
      "last_synced_at": "2026-11-10T15:19:02.329Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • New York, New York + 3 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01323751"
    },
    {
      "nct_id": "NCT04875351",
      "title": "Breast Cancer Index (BCI) Registry",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Biotheranostics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 3465,
      "start_date": "2021-04-14",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-10T15:19:02.329Z",
      "location_count": 105,
      "location_summary": "Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 84 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04875351"
    },
    {
      "nct_id": "NCT04423029",
      "title": "A Study of DF6002 Alone and in Combination With Nivolumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "DF6002",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dragonfly Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2020-07-13",
      "completion_date": "2025-11-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-10T15:19:02.329Z",
      "location_count": 21,
      "location_summary": "Orange, California • Denver, Colorado • New Haven, Connecticut + 17 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04423029"
    },
    {
      "nct_id": "NCT07608731",
      "title": "Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Large B-cell Lymphoma",
        "Central Nervous System Lymphoma"
      ],
      "interventions": [
        {
          "name": "Golcadomide",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allison Winter",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2026-10",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-11-10T15:19:02.329Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07608731"
    }
  ]
}